Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 502-510

  Screnci, D ^a,c   Er, H M ^b   Hambley, T W ^b   Galettis, P ^a   Brouwer, W ^a   McKeage, M J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Anti tumour; Diamino cyclohexane; Neurotoxicity; Platinum; Stereoselectivity

Indexed keywords

OXALIPLATIN; PLATINUM; PLATINUM DERIVATIVE; TETRAPLATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; ENANTIOMER; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTOXICITY; NONHUMAN; OVARY CARCINOMA; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE; SPINAL CORD; SPINAL GANGLION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0030757293     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.416     Document Type: Article

References (36)

1. Anderson WK, Qualigliato DA, Haugwitz RD, Naraynan VL and Wolpert-Defilippes MK (1986) Synthesis, physical properties and antitumour activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 70: 997-1002
2. Appleton TG, Connor JW and Hall JR (1988) S,O- versus S,N- chelation in the reactions of the cis-diamminediaquaplatinum(II) cation with methionine and s-methylcysteine. Inorg Chem 27: 130-137
3. Borch RF (1987) The platinum anti-tumour drugs. In Metabolism and Action of Anti-Cancer Drugs, Powis G and Prough RA (eds), pp 163-193. Taylor and Francis: London
4. Burchenal JH, Kalaher K, O'Toole T and Chisholm J (1977) Lack of cross-resistance between certain platinum coordination compounds in mouse leukaemia. Cancer Res 37: 3455-3457
5. Carfagna PF, Poma A, Wyrick SD, Holbrook DJ and Chaney SG (1991) Comparisons of tetrachloro(d,1-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 27: 335-341
6. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I and Fabbrica D (1992) Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84: 364-371
7. Chaney SG, Wyrick S and Till GK (1990) In vitro biotransformations of tetrachloro(d,1-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res 50: 4539-4545
8. Clarkson TW (1993) Molecular and ionic mimicry of toxic metals. Ann Rev Pharmacol Toxicol 32: 545-571
9. De Koning P, Neijt JP, Jennekens FGI and Gispen WH (1987) Evaluation of cis-diamminedichloroplatinum(II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 89: 81-87
10. Dhara SC (1970) A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J Chem 8: 193-194
11. Drayer DE (1986) Pharmacokinetic and pharmacodynamic differences between drug enantiomers in humans: an overview. Clin Pharm Ther 40: 125-133
12. Eastman A (1987) Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem Pharmacol 36: 4177-4178
13. Extra JM, Espie M, Calvo F, Ferme C, Mignot L and Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299-303
14. Gibbons GR, Wyrick S and Chaney SG (1989) Rapid reduction of tetrachloro(d,1-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res 49: 1402-1407
15. Gregg RW, Molepa JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M and Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time and platinum concentration in neurological tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795-803
16. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP and Harrap KR (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534
17. Hoeschele JD, Farrell N, Turner WR and Rithner CD (1988) Synthesis and characterization of diastereomeric (substituted iminodacetato) (1,2-diaminocyclohexane)platinum(II) complexes. Inorg Chem 21: 4106-4113
18. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52: 3857-3864
19. Kidani Y, Inagaki K, Iigo M, Hoshi A and Kuretani K (1978) Antitumour activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J Med Chem 21: 1315-1318
20. Kido Y, Khokhar AR and Siddik ZH (1993) Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogue isomers in sensitive and resistant cancer cell lines. Anti-Cancer Drugs 4: 251-258
21. Levi F, Misset J, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel J, Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H and Reinberg A (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: high effectiveness against metastatic colorectal cancer. Cancer 69: 893-900
22. McKeage MJ, Boxall F, Jones M and Harrap KR (1994) Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54: 629-631
23. Mauldin SK, Gibbons G, Wyrick SD and Chaney SG (1988) Intracellular biotransformation of platinum compounds with 1,2-diaminocyclohexane carrier ligands in the L1210 cell line. Cancer Res 48: 5136-5144
24. Pendyala L and Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 53: 5970-5976
25. Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD and Trump DL (1994) Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. Cancer Chemother Pharmacol 33: 347-354
26. Rowland M and Tozer TN (1989) Clinical Pharmacokinetics Concepts and Applications. Lea and Febig: Philadelphia
27. Schilder RJ, La Creta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Rody D, Young RC, Ozul RF and O'Dwyer PJ (1994) Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC363812) administered on a day 1 and 8 schedule. Cancer Res 54: 709-717
28. Shimamura A and Fisher DE (1996) p53 in life and death. Clin Cancer Res 2: 435-440
29. Siddik ZH, Jones M, Boxall FE and Harrap KR (1988) Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21: 19-24
30. Siddik ZH, Al-Baker S, Burditt TL and Khokhar AR (1993) Differential antitumour activity and toxicity of isomeric 1,2-diaminocyclohexane platinum(II) complexes. J Cancer Res Clin Oncol 120: 12-16
31. Sorenson CM, Barry MA and Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755
32. Terheggen PMAB, Gerritsen Van Der Hoop R, Floot BGJ and Gispen WH (1989) Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of neuroprotecting peptide ORG.766. Toxicol Appl Pharmacol 99: 334-343
33. Thompson SW, Davies LE, Kornfeld M, Hilgers RD and Standefer JC (1984) Cisplatin neurotoxicity: clinical, electrophysiologic morphologic and toxicologic studies. Cancer 54: 1269-1275
34. Vollano JF, Al-Baker S, Dabrowiak JC and Schurig JE (1987) Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. J Med Chem 30: 716-719
35. Walton MI, Wu E, Koshy P, Sharp SY and Kelland LR (1996) p53 status and CDDP sensitivity in a panel of ovarian cancer cell lines. Proc Am Assoc Cancer Res 37: 402
36. Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD and Griswold DP (1987) Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum(IV) in murine leukaemia L1210 resistant and sensitive to cis-diamminedochloroplatinum(II). Cancer Chemother Pharmacol 20: 96-100